Ready To Launch But Nowhere To Go: Regeneron's Eylea Gets FDA Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech says it is prepared to launch the wet-AMD drug immediately following FDA approval, which is now expected by Nov. 18.
You may also be interested in...
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging
A wave of biotechs is making the milestone move from drug developer to drug marketer, but investors are less interested than ever in sticking around for the potential long-term rewards.